Cathepsin S, on the other hand, is a target for the treatment of inflammatory diseases, such as rheumatoid arthritis and pulmonary fibrosis, and several cathepsin S inhibitors, e.g., petesicatib (Roche, Basel, Switzerland), have shown potential in clinical trials [13,14]. Here, CTSS is linked to rheumatoid arthritis.